Meira G Tx Holdings PLC MGTX
We take great care to ensure that the data presented and summarized in this overview for MeiraGTx Holdings plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MGTX
View all-
Perceptive Advisors LLC New York, NY11.3MShares$48.2 Million1.38% of portfolio
-
Johnson & Johnson New Brunswick, NJ6.64MShares$28.2 Million9.66% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.23MShares$22.2 Million0.04% of portfolio
-
Prosight Management, LP Dallas, TX4.35MShares$18.5 Million5.72% of portfolio
-
Black Rock Inc. New York, NY2.52MShares$10.7 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY2.5MShares$10.6 Million0.96% of portfolio
-
Royce & Associates LP755KShares$3.21 Million0.03% of portfolio
-
State Street Corp Boston, MA569KShares$2.42 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA496KShares$2.11 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX463KShares$1.97 Million0.0% of portfolio
Latest Institutional Activity in MGTX
Top Purchases
Top Sells
About MGTX
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Insider Transactions at MGTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 12
2024
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+9.07%
|
$5,000,000
$4.0 P/Share
|
|
Jun 05
2024
|
Keith R. Harris |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+37.5%
|
-
|
|
Jun 05
2024
|
Martin Indyk |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+36.36%
|
-
|
|
May 28
2024
|
Richard Giroux CFO & COO |
SELL
Bona fide gift
|
Direct |
3,000
-0.36%
|
-
|
|
Apr 05
2024
|
Alexandria Forbes PRESIDENT & CEO |
SELL
Bona fide gift
|
Direct |
1,000
-0.07%
|
-
|
|
Mar 12
2024
|
Alexandria Forbes PRESIDENT & CEO |
SELL
Bona fide gift
|
Direct |
2,000
-0.15%
|
-
|
|
Feb 29
2024
|
Richard Giroux CFO & COO |
SELL
Bona fide gift
|
Direct |
13,500
-1.58%
|
-
|
|
Jan 14
2024
|
Alexandria Forbes PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,863
-1.14%
|
$95,178
$6.36 P/Share
|
|
Jan 14
2024
|
Alexandria Forbes PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.11%
|
-
|
|
Jan 14
2024
|
Robert K Zeldin CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
14,756
-14.12%
|
$88,536
$6.36 P/Share
|
|
Jan 14
2024
|
Robert K Zeldin CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+26.41%
|
-
|
|
Jan 14
2024
|
Richard Giroux CFO & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,219
-1.52%
|
$79,314
$6.36 P/Share
|
|
Jan 14
2024
|
Richard Giroux CFO & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+2.8%
|
-
|
|
Jan 14
2024
|
Robert J Wollin GENERAL COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
2,644
-14.87%
|
$15,864
$6.36 P/Share
|
|
Jan 14
2024
|
Robert J Wollin GENERAL COUNSEL AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+21.95%
|
-
|
|
Jan 14
2024
|
Stuart Naylor CHIEF DEV. OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
11,163
-1.94%
|
$66,978
$6.36 P/Share
|
|
Jan 14
2024
|
Stuart Naylor CHIEF DEV. OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
23,750
+3.96%
|
-
|
|
Jan 08
2024
|
Richard Giroux CFO & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,829
-2.3%
|
$118,974
$6.63 P/Share
|
|
Jan 08
2024
|
Richard Giroux CFO & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+4.17%
|
-
|
|
Jan 08
2024
|
Stuart Naylor CHIEF DEV. OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
18,800
-3.3%
|
$112,800
$6.63 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.25M shares |
|---|---|
| Exercise of conversion of derivative security | 653K shares |
| Payment of exercise price or tax liability | 305K shares |
|---|---|
| Bona fide gift | 19.5K shares |
| Other acquisition or disposition | 6.64M shares |